Cytokinetics gets the Royalty treatment, snagging up to $450M to support closely watched heart programs

Cytokinetics stumbled a bit with its closely watched lead heart drug over the last year or so, losing two pharma partners after missing a key secondary endpoint in a Phase III study. But things are looking up in 2022, as Royalty Pharma is reaching a little deeper into its...

Click to view original post